Close
Almac
Achema middle east

Peli BioThermal Presents Industry Best Practices at ISTA Forum

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.
- Advertisement -

Peli BioThermal, the life science industry’s cold chain partner from discovery to distribution, announces its participation in the 2022 International Safe Transit Association (ISTA) Forum TempPack trade show April 11-13 in San Diego, Calif. The organisation’s Director of Research and Development, Bill Mayer, is a member of the ISTA Pharma Committee and will speak at the event.

“ISTA does important work globally to advance the field of temperature controlled performance packaging,” said David Williams, President of Peli BioThermal. “We are grateful for the opportunity to contribute to this work alongside industry peers and customers of temperature controlled solutions.”

For more than a year, the ISTA Pharma Committee and a group of end users and solutions providers came together to develop a best practices white paper on Ambient Temperature Profiles (ATPs). Mayer and Carolyn Williamson, President of Parenteral Supply Chain, LLC, led the group through the writing process and will present the paper on April 12 at 2 p.m. in the session titled “Ambient Temperature Profile Best Practice Paper.” The presentation will cover currently available industry ATPs, creating and defending an ATP, and how to characterise and compare ATPs.

Mayer will also participate in a panel discussion at 4 p.m. on the same day focusing on industry sharing with lane data. In addition to Mayer’s participation, Kai Goellner, Principal Product Development Engineer at Peli BioThermal, will share his insights on sustainability in a panel discussion on April 13 at 11:15 a.m. Goellner is responsible for Peli BioThermal’s award-winning sustainability work and white paper titled “An Environmental Impact Comparison of Packaging Methods in the Cold Chain Industry,” which compares the environmental impact of single-use and reusable shippers.

Company: Peli BioThermal Limited


Pharmaceutical companies and other organisations looking to make significant cost and quality improvements in their cold chains are switching to Peli BioThermal for single-use and reusable temperature-controlled packaging. Our innovative, patented technologies and consultative services ensure product quality, mitigate excursion rates, reduce packaging costs and drive Total Cost of Ownership (TCO) across your entire supply chain. Our global network of consultative cold chain experts provides our customers with consistent packaging and logistics experiences wherever they do business. While our full line of single use and reusable packaging solutions from parcel to pallet shippers are competitively priced, the real economic value we bring to our customers focuses on TCO.

Send Enquiry for this story

By submitting this form you agree to allow www.worldpharmatoday.com to contact you regarding your enquiry.
See our Privacy Policy to learn more.

Latest stories

Related stories

First GLP-1 Pill for Obesity by Novo Nordisk Approved by FDA

The U.S. Food and Drug Administration – FDA on...

How High-Achievers Stay Future-Ready in Evolving Job Markets

Job markets today are transforming rapidly. In the past...

Proactive Risk Management as a Core Capability in Pharma Development

Risk management in pharma is often treated as a reactive compliance box-ticking exercise. This article argues for reframing risk as a strategic competitive advantage. It details proactive frameworks like the "Excipient Exclusion Filter," Decision Quality (DQ) matrices, and "pre-mortem" analyses that allow development teams to anticipate failure modes and engineer them out of the pipeline before they occur.

Rethinking Pipeline Value Beyond Peak Sales Forecasts

The traditional reliance on risk-adjusted Net Present Value (rNPV) and peak sales forecasts is failing to capture the true potential of modern pharmaceutical assets, particularly platform technologies. This article introduces holistic valuation frameworks like Real Options Analysis (ROA) and the Platform VISTA model, arguing for a shift toward valuing "strategic fit," "lifecycle potential," and the intangible equity of innovation engines.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »